Wellington Management Group LLP Boosts Holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO)

Wellington Management Group LLP boosted its stake in Organogenesis Holdings Inc. (NASDAQ:ORGO) by 8.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 241,648 shares of the company’s stock after buying an additional 17,842 shares during the quarter. Wellington Management Group LLP owned approximately 0.18% of Organogenesis worth $691,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. AQR Capital Management LLC lifted its stake in shares of Organogenesis by 76.9% in the second quarter. AQR Capital Management LLC now owns 2,268,760 shares of the company’s stock worth $6,353,000 after buying an additional 986,132 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Organogenesis by 19.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,036,743 shares of the company’s stock worth $5,702,000 after purchasing an additional 333,123 shares during the last quarter. Wealth Dimensions Group Ltd. increased its stake in shares of Organogenesis by 435.9% in the 2nd quarter. Wealth Dimensions Group Ltd. now owns 407,965 shares of the company’s stock worth $1,142,000 after acquiring an additional 331,840 shares during the last quarter. Cubist Systematic Strategies LLC increased its position in Organogenesis by 1,350.3% during the second quarter. Cubist Systematic Strategies LLC now owns 94,705 shares of the company’s stock worth $265,000 after purchasing an additional 88,175 shares during the last quarter. Finally, Acadian Asset Management LLC raised its position in shares of Organogenesis by 2.4% during the 2nd quarter. Acadian Asset Management LLC now owns 3,074,375 shares of the company’s stock valued at $8,605,000 after buying an additional 72,696 shares during the period. 49.57% of the stock is currently owned by hedge funds and other institutional investors.

Organogenesis Trading Down 1.9 %

ORGO opened at $3.05 on Friday. The business’s 50 day moving average price is $3.46 and its 200 day moving average price is $3.01. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09. The stock has a market capitalization of $404.36 million, a PE ratio of -50.83 and a beta of 1.73. Organogenesis Holdings Inc. has a one year low of $2.16 and a one year high of $4.70.

Organogenesis (NASDAQ:ORGO) last announced its quarterly earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.11. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. The firm had revenue of $115.18 million during the quarter, compared to the consensus estimate of $109.59 million. During the same period in the prior year, the company posted $0.02 earnings per share. As a group, equities research analysts expect that Organogenesis Holdings Inc. will post -0.07 EPS for the current year.

Insider Buying and Selling

In other Organogenesis news, CEO Gary S. Gillheeney sold 55,615 shares of Organogenesis stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $3.36, for a total value of $186,866.40. Following the sale, the chief executive officer now owns 3,044,779 shares of the company’s stock, valued at approximately $10,230,457.44. The trade was a 1.79 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 278,116 shares of company stock valued at $991,190 over the last quarter. 36.90% of the stock is currently owned by insiders.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.